The Pharmacy Times® Lymphoma Resource Center is a comprehensive resource for clinical news and expert insights on treatments for lymphoma, a cancer that begins in cells of the lymph system. Common treatments for lymphoma may involve chemotherapy, medication, radiation therapy, and stem cell transplant.
April 19th 2024
Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strategies
1.0 Credit / Oncology, Hematologic Cancer
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
1.0 Credit / Hematologic Cancer, Oncology
View More
Optimizing Bispecific Antibody Utilization in Non-Hodgkin Lymphoma: Addressing Challenges in Community-Based Care
1.0 Credit / Hematologic Cancer, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success
1.0 Credit / Hematologic Cancer
View More
Optimizing JAK Inhibitor Therapy for Myelofibrosis: Insights for Oncology Pharmacists
1.0 Credit / Hematologic Cancer, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Practice
1.0 Credit / Hematologic Cancer, Oncology
View More
Balancing Innovation and Implementation: A Comprehensive Approach to CAR T, Bispecific Antibodies, and Operational Efficiency in Multiple Myeloma
1.0 Credit / Hematologic Cancer, Oncology
View More
Navigating Chronic Lymphocytic Leukemia Therapy and Cardiovascular Comorbidities: Clinical Recommendations and Safety Measures
1.0 Credit / Hematologic Cancer
View More
Finding Balance Between Advancement and Application: A Guide for Community Oncology Pharmacists on CAR T-Cell Therapies and Bispecific Antibodies in Multiple Myeloma
0.75 Credit / Oncology, Hematologic Cancer
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
1.5 Credits / Hematology, Hematologic Cancer, Oncology
View More
Expert: Unmet Need for Accessible, Effective, Tolerable Therapy for Older Patients With R/R DLBCL
December 13th 2022Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Pharmacists in the Oncology Setting: Financial and Clinical Impact is Significant
November 3rd 2022In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.
Read More
Interim FDG-PET/CT May Have Positive Prognostic Value for Hodgkin’s Lymphoma
October 26th 2022Research suggests that positron emission tomography scans are effective at detecting early and late Hodgkin’s lymphoma, and the results could help manage and reduce toxicity from current chemotherapies.
Read More
How Cancer Vaccines Can Educate an Immune Response in Advanced Cancer Patients
October 13th 2022Jeremy Graff, chief scientific officer at IMV, discusses why the development of viable cancer vaccines is a bit more slow-going in comparison to the fast-paced development of COVID-19 vaccines during the pandemic.
Watch